286 related articles for article (PubMed ID: 21842452)
1. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
Fresard I; Bridevaux PO; Rochat T; Janssens JP
Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452
[TBL] [Abstract][Full Text] [Related]
2. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
Simkins J; Abbo LM; Camargo JF; Rosa R; Morris MI
Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035
[TBL] [Abstract][Full Text] [Related]
3. Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center.
Arguello Perez E; Seo SK; Schneider WJ; Eisenstein C; Brown AE
Clin Infect Dis; 2017 Nov; 65(12):2105-2111. PubMed ID: 29020308
[TBL] [Abstract][Full Text] [Related]
4. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
Gray EL; Goldberg HF
Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.
Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Barbeau P; Skidmore B; Alvarez GG
Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):557-566. PubMed ID: 29573031
[TBL] [Abstract][Full Text] [Related]
6. Treatment of latent tuberculosis infection: An update.
Lobue P; Menzies D
Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026
[TBL] [Abstract][Full Text] [Related]
7. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period.
Jahng AW; Tran T; Bui L; Joyner JL
Transplantation; 2007 Jun; 83(12):1557-62. PubMed ID: 17589337
[TBL] [Abstract][Full Text] [Related]
8. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review.
Kunst H; Khan KS
Int J Tuberc Lung Dis; 2010 Nov; 14(11):1374-81. PubMed ID: 20937175
[TBL] [Abstract][Full Text] [Related]
9. Reparation of Isoniazid and Rifampicin Combinatorial Therapy-Induced Hepatotoxic Effects by Bacopa monnieri.
Evan Prince S; Udhaya LB; Sunitha PS; Arumugam G
Pharmacology; 2016; 98(1-2):29-34. PubMed ID: 27007136
[TBL] [Abstract][Full Text] [Related]
10. Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital.
Chung SJ; Lee H; Koo GW; Min JH; Yeo Y; Park DW; Park TS; Moon JY; Kim SH; Kim TH; Sohn JW; Yoon HJ
Sci Rep; 2020 Apr; 10(1):6462. PubMed ID: 32296096
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
Tseng SY; Huang YS; Chang TE; Perng CL; Huang YH
J Chin Med Assoc; 2021 Nov; 84(11):993-1000. PubMed ID: 34747900
[TBL] [Abstract][Full Text] [Related]
12. Naringenin protects against isoniazid- and rifampicin-induced apoptosis in hepatic injury.
Wang C; Fan RQ; Zhang YX; Nie H; Li K
World J Gastroenterol; 2016 Nov; 22(44):9775-9783. PubMed ID: 27956801
[TBL] [Abstract][Full Text] [Related]
13. Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment.
Bray MG; Poulain C; Dougados M; Gossec L
Joint Bone Spine; 2010 Mar; 77(2):135-41. PubMed ID: 20097592
[TBL] [Abstract][Full Text] [Related]
14. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis.
Long MW; Snider DE; Farer LS
Am Rev Respir Dis; 1979 Jun; 119(6):879-94. PubMed ID: 110184
[TBL] [Abstract][Full Text] [Related]
15. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.
Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE
Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943
[TBL] [Abstract][Full Text] [Related]
16. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy.
Li F; Lu J; Cheng J; Wang L; Matsubara T; Csanaky IL; Klaassen CD; Gonzalez FJ; Ma X
Nat Med; 2013 Apr; 19(4):418-20. PubMed ID: 23475203
[TBL] [Abstract][Full Text] [Related]
17. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
18. Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.
Fluegge KR
J Eval Clin Pract; 2014 Oct; 20(5):685-91. PubMed ID: 25087583
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
[TBL] [Abstract][Full Text] [Related]
20. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?
Gordin FM; Cohn DL; Matts JP; Chaisson RE; O'Brien RJ; ; ;
Clin Infect Dis; 2004 Aug; 39(4):561-5. PubMed ID: 15356822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]